Drug Trial Radar · NCT04839367
Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)
Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 13, 2021
Primary completion
Oct 19, 2022
Study completion Oct 19, 2022
Sponsor
- Lead sponsor
- Clarity Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
Conditions
- Prostatic Neoplasms
Interventions
64Cu-SAR-bisPSMADrug
64Cu-SAR-bisPSMA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of 64Cu-SAR-bisPSMA using Common Terminology Criteria for Adverse Events version 5Time frame: 11 weeks
- Efficacy of 64Cu-SAR-bisPSMA in the Detection of Primary Prostate Caner Compared to HistopathologyTime frame: 11 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Nepean Hospital
Kingswood, New South Wales, Australia
St. Vincent's Hospital
Sydney, New South Wales, Australia
GenesisCare CTA, SJOG Medical Clinic
Murdoch, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.